VRC01 Pharmacokinetics at Mucosal Sites in HIV-infected and Healthy Adults

被引：0

作者：

Prabhakaran, Madhu S. P. ^{[1
]}

Narpala, Sandeep R. ^{[1
]}

Lin, Chien L. ^{[1
]}

Bailer, Robert T. ^{[1
]}

Shi, Wei ^{[1
]}

Chen, Xuejun ^{[1
]}

Kong, Wing-Pui ^{[1
]}

Ledgerwood, Julie ^{[1
]}

Koup, Richard A. ^{[1
]}

McDermott, Adrian B. ^{[1
]}

机构：

[1] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD USA

来源：

AIDS RESEARCH AND HUMAN RETROVIRUSES | 2018年 / 34卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

OA08.04

引用

页码：35 / 35

页数：1

共 50 条

[21] Population pharmacokinetics (PK) of nevirapine (NVP) in HIV-infected adults
Schipani, A.
Wakeham, K.
Ggayi, A.
Kamali, A.
Lalloo, D. G.
Youle, M.
Johnson, M.
Khoo, S.
Dickinson, L.
Back, D.
HIV MEDICINE, 2009, 10 : 51 - 51
[22] HIV VRC01单链抗体的构建、原核表达及纯化
王瑞琴
杨雄
陈红英
西北农林科技大学学报(自然科学版), 2013, 41 (01) : 177 - 182+194
[23] Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound
Cale, Evan M.
Bai, Hongjun
Bose, Meera
Messina, Michael A.
Colby, Donn J.
Sanders-Buell, Eric
Dearlove, Bethany
Li, Yifan
Engeman, Emily
Silas, Daniel
O'Sullivan, Anne Marie
Mann, Brendan
Pinyakorn, Suteeraporn
Intasan, Jintana
Benjapornpong, Khunthalee
Sacdalan, Carlo
Kroon, Eugene
Phanuphak, Nittaya
Gramzinski, Robert
Vasan, Sandhya
Robb, Merlin L.
Michael, Nelson L.
Lynch, Rebecca M.
Bailer, Robert T.
Pagliuzza, Amelie
Chomont, Nicolas
Pegu, Amarendra
Doria-Rose, Nicole A.
Trautmann, Lydie
Crowell, Trevor A.
Mascola, John R.
Ananworanich, Jintanat
Tovanabutra, Sodsai
Rolland, Morgane
JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (06): : 3299 - 3304
[24] Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features
Magaret, Craig A.
Benkeser, David C.
Williamson, Brian D.
Borate, Bhavesh R.
Carpp, Lindsay N.
Georgiev, Ivelin S.
Setliff, Ian
Dingens, Adam S.
Simon, Noah
Carone, Marco
Simpkins, Christopher
Montefiori, David
Alter, Galit
Yu, Wen-Han
Juraska, Michal
Edlefsen, Paul T.
Karuna, Shelly
Mgodi, Nyaradzo M.
Edugupanti, Srilatha
Gilbert, Peter B.
PLOS COMPUTATIONAL BIOLOGY, 2019, 15 (04) : 1 - 35
[25] Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial
Mayer, Kenneth H.
Seaton, Kelly E.
Huang, Yunda
Grunenberg, Nicole
Isaacs, Abby
Allen, Mary
Ledgerwood, Julie E.
Frank, Ian
Sobieszczyk, Magdalena E.
Baden, Lindsey R.
Rodriguez, Benigno
Hong Van Tieu
Tomaras, Georgia D.
Deal, Aaron
Goodman, Derrick
Bailer, Robert T.
Ferrari, Guido
Jensen, Ryan
Hural, John
Graham, Barney S.
Mascola, John R.
Corey, Lawrence
Montefiori, David C.
PLOS MEDICINE, 2017, 14 (11)
[26] Safety and virologic effect of the HIV-1 broadly neutralizing antibodies, VRC01LS or VRC07-523LS, administered to HIV-infected adults in a phase 1 clinical trial
Chen, G.
Coates, E.
Fichtenbaum, C.
Koletar, S.
Landovitz, R.
Presti, R.
Overton, T.
Santana, J.
Rothwel, R. S.
Roa, J.
Donaghy, E.
Holman, L.
Novik, L.
Berkowitz, N.
Larkin, B.
Conan-Cibotti, M.
Tressler, R.
Wang, J.
Hu, Z.
Capparelli, E.
Arnold, F.
Bailer, R.
McDermott, A.
Gama, L.
Graham, B.
Koup, R.
Mascola, J.
Ledgerwood, J.
Tebas, P.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 100 - 101
[27] Prediction of VRC01 Neutralization Sensitivity by HIV-1 gp160 Sequence Features
Magaret, Craig A.
Williamson, Brian D.
Borate, Bhavesh
Carpp, Lindsay
Georgiev, Ivelin
Setliff, Ian
Dingens, Adam S.
Benkesser, David C.
Simon, Noah
Carone, Marco
Montefiori, David
Alter, Galit
Yu, Wen-Han
Juraska, Michal
Edlefsen, Paul T.
Karuna, Shelly
Mgodi, Nyaradzo M.
Edugupanti, Srilatha
Gilbert, Peter B.
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2018, 34 : 344 - 344
[28] Expression of a functional B cell receptor with the specificity of VRC01, a broadly neutralizing antibody against HIV
Guo, Xiaoti
Yang, Zhiyong
Panet, Amos
Liu, Wanli
Pierce, Susan
Nabel, Gary
JOURNAL OF IMMUNOLOGY, 2011, 186
[29] Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
Yunda Huang
Lily Zhang
Shelly Karuna
Philip Andrew
Michal Juraska
Joshua A. Weiner
Heather Angier
Evgenii Morgan
Yasmin Azzam
Edith Swann
Srilatha Edupuganti
Nyaradzo M. Mgodi
Margaret E. Ackerman
Deborah Donnell
Lucio Gama
Peter L. Anderson
Richard A. Koup
John Hural
Myron S. Cohen
Lawrence Corey
M. Juliana McElrath
Peter B. Gilbert
Maria P. Lemos
Nature Communications, 14
[30] Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features
Juraska, Michal
Bai, Hongjun
deCamp, Allan C.
Magaret, Craig A.
Li, Li
Gillespie, Kevin
Carpp, Lindsay N.
Giorgi, Elena E.
Ludwig, James
Molitor, Cindy
Hudson, Aaron
Williamson, Brian D.
Espy, Nicole
Simpkins, Brian
Rudnicki, Erika
Shao, Danica
Rossenkhan, Raabya
Edlefsen, Paul T.
Westfall, Dylan H.
Deng, Wenjie
Chen, Lennie
Zhao, Hong
Bhattacharya, Tanmoy
Pankow, Alec
Murrell, Ben
Yssel, Anna
Matten, David
York, Talita
Beaume, Nicolas
Gwashu-Nyangiwe, Asanda
Ndabambi, Nonkululeko
Thebus, Ruwayhida
Karuna, Shelly T.
Morris, Lynn
Montefiori, David C.
Hural, John A.
Cohen, Myron S.
Corey, Lawrence
Rolland, Morgane
Gilbert, Peter B.
Williamson, Carolyn
Mullins, James I.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2024, 121 (04)

← 1 2 3 4 5 →